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Abstract
The development of novel therapeutic agents is essential for combating the increasing number of cases of dengue
fever in endemic countries and among a large number of travelers from non-endemic countries. The dengue virus
has three structural proteins and seven non-structural (NS) proteins. NS3 is a multifunctional protein with an
N-terminal protease domain (NS3pro) that is responsible for proteolytic processing of the viral polyprotein, and a
C-terminal region that contains an RNA triphosphatase, RNA helicase and RNA-stimulated NTPase domain that are
essential for RNA replication. The serine protease domain of NS3 plays a central role in the replicative cycle of den-
guevirus.ThisreviewdiscussestherecentstructuralandbiologicalstudiesontheNS2B-NS3protease-helicaseand
considers the prospects for the development of small molecules as antiviral drugs to target this fascinating,
multifunctional protein.
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Introduction
The genus Flavivirus in the family Flaviviridae con-
tains a large number of viral pathogens that cause severe
morbidity and mortality in humans and animals (Bancroft,
1996). In endemic areas, dengue virus is transmitted by the
main mosquito vector, Stegomyia aegypti (formerly
Aedes), and circulates as a complex of four serotypes,
DENV1 to DENV4 (Bancroft, 1996), that are all causative
agentsofdenguefever,denguehemorrhagicfeverandden-
gueshocksyndrome.Thehighburdenonpublichealthcare
and the limited options of therapy for dengue diseases have
stimulated efforts to identify and characterize potential vi-
ral drug targets, such as the non-structural protein 3 (NS3)
serineproteases,andtodesignandevaluateantiviralinhibi-
tors that are equally effective against the four dengue virus
serotypes and related members of the Flaviviridae (Lin-
denbach and Rice, 2007).
The positive-sense flavivirus RNA genome of 11 kb
forms a single open reading frame that is translated into an
~370 kDa polyprotein precursor containing the structural
proteins C, prM, and E and seven non-structural proteins
knownasNS1,NS2A,NS2B,NS3,NS4A,NS4BandNS5.
The polyprotein is co- and post-translationally cleaved by
host cell proteases and the viral protease NS3 into three
structural proteins (Capsid, premembrane and envelope
proteins) that are components of the virion, and at least
seven non-structural proteins involved in viral replication
and maturation (Henchal and Putnak, 1990; Kautner et al.,
1996). The virus-encoded protease complex NS2B-NS3 is
responsible for cleaving the NS2A/NS2B, NS2B/NS3,
NS3/NS4A and NS4B/NS5 junctions and the Capsid pro-
tein.
Dengue diseases are caused by the four antigenically
distinct dengue virus serotypes, DENV1-4. Current evi-
dence suggests that the two virus-encoded non-structural
proteins NS3 and NS5 that contain the key enzymes re-
quired for RNA replication are sufficiently conserved
within the four serotypes to permit the design of com-
pounds that will be active against all dengue virus strains
and other related flaviviruses such as YFV, 70 WNV and
JEV(Lietal.,2005;Kelleretal.,2006).Sincedenguevirus
and hepatitis C virus (HCV) are members of the
Flaviviridae, it is interesting to compare the conditions that
they cause: dengue produces an acute self-limiting illness
whereas HCV provokes a chronic disease that can poten-
tially lead to hepatocarcinoma. Given the short period of
viremia, the question often posed is what benefit an antivi-
ral compound would have in treating patients with dengue.
Epidemiologicalstudieshaveindicatedthatseriousdengue
diseases are often associated with high levels of circulating
virus (Gubler et al., 1981; Libraty et al., 2002). Conse-
quently, if dengue fever is diagnosed at an early stage
through identification of the viral genome by RT-PCR or
the presence of circulating NS1 protein in the blood, then
antiviraltreatmentcouldbeusefulinlimitingtheviralload,
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Review Articlethereby reducing the severity of the disease (Keller et al.,
2006). In the case of epidemics, one could also envision the
use of prophylactic treatment to target groups of patients
identifiedthroughdecisiontreealgorithmsbasedonsimple
clinical and hematological parameters (Tanner et al.,
2008).
The identification of novel antiviral compounds ac-
tive against dengue enzymes that are essential for viral rep-
lication required detailed 3D structural studies of the two
multifunctionalproteinsNS3andNS5.Therecentdetermi-
nationofthe3Dstructuresofthemajorreplicativeenzymes
fromflaviviruses,particularlytheproteinNS3,isdiscussed
below.Thisproteincontainsaserineproteasedomaininthe
N-terminal region that requires the formation of a non-co-
valent complex with the membrane-bound cofactor NS2B
for activity, and has ATP-driven helicase and RNA tri-
phosphatase activities in the C-terminal region (Figure 1).
Interestingly, NS3 is apparently also involved in virus as-
sembly via mechanisms that are independent of the enzy-
matic functions outlined above (Khromykh et al., 2001;
Patkar and Kuhn, 2008).
Dengue Virus Life Cycle
The dengue viral particle consists of a lipid bilayer
surrounding a capsid that contains the 10.7 kb positive-
strand RNA genome (Lindenbac et al., 2007). The viral
RNAcontainsatypeImethyl-guanosinecapstructureatits
5’end but is devoid of a poly-adenylate tail (Ray et al.,
2006). The first step in viral infection is the binding to a
cell-surface receptor (Chu et al., 2005; Fink et al., 2006)
that results in major structural changes in the surface enve-
lope glycoprotein E, a class I viral fusion glycoprotein. Vi-
ral entry subsequently occurs via endocytosis, with acidifi-
cation of the endosome (Roussel et al., 2006) leading to the
merging of host and virus lipid membranes (Bressanelli et
al., 2004; Modis et al., 2004) and the release of viral
genomic RNA into the host cell cytoplasm. The dengue vi-
rus genome encodes an uninterrupted open reading frame
of 10,173 nucleotides that is translated into a polyprotein
precursor 3391 amino acids long. The order of proteins in
this precursor is: C-prM-E-NS1-NS2-NS2A-NS2B-NS3-
NS4A-NS4B-NS5. The polyprotein is co- and post-trans-
lationally cleaved by host cell proteases and the viral prote-
ase NS3 into three structural proteins (Capsid,
premembrane and envelope proteins) that are components
of the virion and at least seven non-structural proteins in-
volved in virus replication and maturation (Bera et al;,
2007). Once the viral polymerase NS5 has been synthe-
sized and released from the polyprotein precursor, the viral
RNA is transcribed, starting from the 3’end, into the com-
plementary minus strand RNA that is then transcribed back
into a positive strand. The transient dsRNA intermediate
formed during this process must be separated into its indi-
vidual strands in order to provide access to the NS5 poly-
merase for further rounds of viral genome replication (Bera
et al;, 2007).
You et al. (2001) and Yon et al. (2005) provided de-
tailed descriptions of the structural requirements for the
RNA molecule that ensure viral RNA synthesis. These in-
cludeapromoterregionlocatedasthe5’endofthegenome
towhichtheNS5polymerasedirectlybinds,aswellaslong
range RNA-RNA interactions between stem-loop forming
motifs located at the 5’ and 3’ ends of the viral genome that
lead to its cyclization. NS3, which physically associates
with the NS5 polymerase (Johansson et al., 2001; You et
al., 2001), has an essential role in the viral life cycle since
mutagenesis studies have shown that impairment of either
its proteolytic or NTPase/helicase activity leads to a defec-
tive genome unable to produce infectious viral particles
(Matusan et al., 2001).
The most conserved flavivirus protein is NS5, which
hasamethyltransferasemotifintheN-terminaldomainand
an RNA-dependent RNA polymerase in its C-terminal do-
main (Tan et al., 1996). After processing of the viral pro-
teins, most of the NS proteins associate with the 3’-UTR of
viral RNA to form a replication complex for RNA synthe-
sis. The association of protein C with genomic RNA on the
cytosolic face of the endoplasmic reticulum membrane is
the initial step of virion assembly. The particles are trans-
ported via the secretary pathway to the cell surface for re-
lease.
The Ns2b-Ns3pro Complex
The serine protease domain of NS3 is located in the
first 180 amino acids of the N-terminal region of this
multifunctional protein (Figure 1). The NS3 protease,
whichisalsoconsideredamemberoftheflavivirinenzyme
family (EC 3.4.21.91 and S07.001 Peptidase MEROPS
peptidase database), has a tendency to form aggregates and
is enzymatically inactive. The presence of a small activat-
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Figure 1 - Schematic representation of the flaviviviral polyprotein with
the cleavage sites processed by NS2B-NS3pro indicated by arrows. Also
shown is the partition of the various functional domains along the primary
sequence of NS2B-NS3. The regions of the NS2B proteins expected to as-
sociate with membranes are indicated as filled boxes. Evolutionarily con-
served residues essential for NS3 enzymatic activities are indicated.ing cofactor protein is a prerequisite for optimal catalytic
activityofflaviviralproteaseswithnaturalpolyproteinsub-
strates(Lietal.,2005).Thiscofactor,whichisacentralhy-
drophilic portion (spanning residues 49-95) of the integral
membraneproteinNS2B,isrequiredforviralproteaseacti-
vation (Falgout et al., 1991; Keller et al., 2006), including
thatofNS3(Erbeletal.,2006)(Figure1).TheNS2B-NS3
conjugate cleaves the precursor polyprotein at
NS2A/NS2B, NS2B/NS3, NS3/NS4A and NS4B/NS5
junctions, as well as at internal sites within C, NS2A, NS3
and NS4A (Falgout et al., 1991). NS2B consists of seven
domains (I - VII) that can be separated on the basis of their
relative hydrophobicity (Falgout et al., 1991). The hydro-
phobic core residues belonging to domain IV (G69-E80)
were proposed to interact with NS3pro. This domain is
flanked by two hydrophilic stretches (domains III and V).
Studies using mutant plasmids transfected into cells have
shown that a fragment of 40 residues encompassing do-
mains III to V is the minimal region necessary for inducing
theproteaseactivityofNS3pro(Speronietal.,2007).Inad-
dition, co-immunoprecipitation experiments have shown
thattheNS2B-NS3associationisalsomediatedbythishy-
drophilic region (Chambers et al., 1991).
Comparison of the kinetic properties of NS3 and
NS2B - NS3 suggests that NS2B generates additional spe-
cific interactions with the substrate residues P2 and P3
(Chambers et al., 1990). The molecular mechanism by
which the NS2B cofactor stimulates protease activity is un-
known, although comparison with an analogous HCV pro-
tease has provided some structural and mechanistic expla-
nations for activation of the dengue virus protease by its
cofactor.However,unliketheHCVNS3protein,thecofac-
tor activity for DEN-2 NS3pro cannot be supplied in trans
with a small peptide derived from NS2B (Bartenschlager et
al., 1995). Other serine proteases (subtilisin, -lytic prote-
ase) also require a pro-region, such as NS2B, to mediate
foldingthatleadstotheactiveform.Inthesecases,oncethe
protein is folded, the necessary pro-region does not remain
bound to the active enzyme.
The active protease has been successfully expressed
by fusing the 5’ end of the NS2B viral cofactor spanning
residues 49-95 (CF40) of DENV2 to amino-acids 1-169 of
the NS3 protein via a flexible glycine linker (Gly4-Ser-
Gly4) linker (Leung et al., 2001). Leung et al. (2001)
cloned and expressed the protease (CF40-Gly4-Ser-Gly4-
NS3pro) from all four dengue serotypes (DENV 1-4) and
used the in vitro assay described by Erbel et al. (2006) to
screen a tetrapeptide library containing more than 130,000
substrates. The tetrapetide benzoyl-norleucine (P4) - lysine
(P3) - arginine (P2) - arginine (P1) - ACMC (Bz-Nle-Lys-
Arg-Arg-ACMC) was identified as the optimal substrate
with the steady state kinetics parameter 176 kcat/Kmo f
51,800 M
-1s
-1, which is > 150-fold more sensitive than for
other peptides. This sensitivity allowed the assay to be
scaled down for high-throughput screening (Yusof et al.,
2000). The tetrapeptide aldehyde Bz-Nle-Lys-Arg-Arg-H,
a competitive inhibitor of the protease domain and of the
full length NS3protein with its cofactor (CF40-Gly4-Ser-
Gly4-NS3FL) (Kio f5 . 8M and 7.0 M, respectively) has
been used in structure - activity relationship (SAR) experi-
ments to identify more potent inhibitors. This approach has
allowedthedevelopmentofcompoundsbasedonstrategies
used to overcome the shallow binding pocket of the HCV
protease. A high resolution analysis of the interaction be-
tween NS3 and NS2B using the tetrapeptide aldehyde in-
hibitor indicated that the central hydrophilic portion of the
NS2B cofactor refolds to form an important component of
the protease catalytic site (Erbel et al., 2006). This analysis
provides a basis for screening drugs that can target fla-
viviral proteases, e.g., the apo-enzyme from DENV2 and a
complex formed by the WNV NS2B-NS3Pro enzyme and
Bz-Nle-Lys-Arg-Arg.
In both structures, the N-terminal part of the NS2B
cofactor (residues 49-66) forms a -strand that is inserted
into the N-terminal -barrel of the protease, thereby con-
cealing hydrophobic residues from the solvent and stabiliz-
ing this domain; WNV residues Trp53-Leu54-Glu55-Arg56-
Ala57-Ala58 form a -strand to the N-terminal -barrel of
the NS3 protease (Figure 2). This explains the observed
strongtendencyforNS3proandFLNS3toaggregatewhen
the strand contributed by NS2B is absent in synthetic con-
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Figure2-(A)SchematicrepresentationoftheNS2B-NS3proteaseshow-
ing the apo-enzyme from DENV2 with the NS2B cofactor in dark shade.
The WNV residues Trp53-Arg56 are represented by sticks. (B) NS2B Pro
and NS2B showing important residues.structs. In this respect, the N-terminal of NS2B has a
chaperone-like role in stabilizing NS3. In contrast, the con-
formationoftheC-terminalpartoftheNS2Bcofactoristo-
tally different in the apo- and inhibitor-bound enzymes: a
large rearrangement brings residues 66-88 of NS2B in
close proximity to the substrate-like inhibitor to form a belt
that braces the second chymotrypsin-like -barrel.
Amino-acids Arg78-Leu87 of the NS2B cofactor affect the
formation of the active site by contributing a -hairpin that
insertsintotheC-terminal-barreltherebyreorientingresi-
duesforsubstraterecognition.Nuclearmagneticresonance
experimentshaveshownthatthisC-terminaldomainisdis-
orderedintheabsenceofthesubstrate-likeinhibitorbutbe-
comes ordered upon binding (Erbel et al., 2006). Thus, the
conformation adopted by the C-terminal segment of NS2B
in the apo-enzyme crystal structure is probably only one
amongst those that are accessible in solution and appears to
be dictated by crystal packing forces. The dual role of the
40 amino acid NS2B cofactor region in stabilizing the pro-
tein and forming the active site of the protease is indeed
unique to flaviviruses and distinguishes it from HCV NS3
protease that requires only a 12 amino acid sequence from
NS4A to form the active protein.
Theabilityofaprotinintooccupyallofthespecificity
pockets of the protease with the subsequent formation of a
fully formed oxyanion hole has provided a complete view
of the enzyme-substrate Michaelis complex for a flavivirus
protease (Speroni et al., 2007). Analysis of the resulting
structures has provided new opportunities for discovering
flavivirus-specific drugs that could interfere with protein -
protein interactions required for activation of the protease,
in addition to the development of competitive inhibitors.
Aleshin et al. (2007) reported a search for small molecular
weight inhibitors of flaviviral NS3 protease. Based on ini-
tialscreeningexperiments,Johanssonetal.(2001)selected
a common scaffold that was further improved by targeted
chemical modification during lead optimization to identify
a class of [5-amino-1-(phenyl) sulfonyl-pyrazol-3-yl)]
compounds that may function by blocking the NS2B bind-
ing pocket within NS3, thereby preventing the interaction
between the two proteins that is needed for protease activ-
ity. Structural studies of the NS2B-NS3 complex from
WNV and DENV, together with assays using specific sub-
strates,provideausefulapproachforidentifyinganddevel-
oping novel, selective NS3 protease inhibitors.
The Ns3 Ntpase/Helicase
The 3’ end of NS3 forms the RNA helicase domain,
an ATP-driven molecular motor that modifies the topology
of nucleic acids. The specific role of the helicase domain in
thevirallifecycleisunclear,althoughtheenzymeisgener-
ally believed to separate transient, intermediate dsRNA
formedduringpolymerizationcatalyzedbyNS5viralpoly-
merase into its individual strands (Malet et al., 2007); this
strand separation facilitates further rounds of replication
and transcription. The helicase domain may also facilitate
viral RNA replication by disrupting secondary structures
formed by the ssRNA template or by displacing other host
or viral proteins bound to dsRNA. The ATPase activity of
NS3 is stimulated by RNA, thus highlighting the extensive
cross-talk between the various catalytic centers of the NS3
enzyme. Wu et al. (2005) studied the NS3 helicase/nu-
cleoside triphosphatase catalytic domains of DENV2 and
YFV. The proteins consist of three subdomains of approxi-
mately 140 residues. All seven of the 283 amino-acid se-
quence motifs, including motif I (also known as Walker A,
the phosphate binding loop or P-loop), that have been iden-
tified in members of the SF2 superfamily of helicases
(Gorbalenya and Koonin, 1993) are located in subdomains
1 and 2. Despite the very low level of sequence identity be-
tween them, both subdomains adopt the same / fold ini-
tially identified in the RecA protein (Xu et al., 2005). The
ATP binding site is located between the two subdomains.
The mode of ATP binding was initially visualized through
the suking of ATP (even though only ADP was located in
the binding site, as shown by analysis at very high crystal-
lographic temperatures) and by comparison with models of
other ATP-driven DNA helicases. These analyses sug-
gested that ATP was bound primarily through its triphos-
phate moiety via contacts mediated by residues emanating
fromtheP-loopandDEAHmotifII(orWalkerBmotif).In
DENV 4 helicase bound to ADP and AMP PNP, adenylyl
imidodiphosphate contact with the 3’OH group of ribose is
direct whereas contact with the 2’OH is mediated by a wa-
ter molecule. The ATP-binding domain is structurally well
conserved when compared to other SF2 helicases, includ-
ing that of HCV, with subdomian 3 of the flavivirus heli-
case being the most divergent (Xu et al., 2005). Kapoor et
al. (1995) attempted to reconcile the structural diversity
amongtherespectivepolymerasesandthewaytheyassoci-
ate with NS3 subdomain 3 to form the replication complex.
Kim et al. (1998) proposed that a groove located at the
interface between the three subdomains housed a single-
stranded nucleic acid substrate of approximately 6-8 ribo-
nucleotides that would form the 3’ overhang needed by the
enzyme to translocate along the substrate during unwind-
ing. Sampath et al. (2001) used site-directed mutagenesis
of full-length NS3 to examine the effect of Ala substitu-
tions in subdomain 2 on the ATPase, helicase and RTPase
activities of this protein. Since an excellent correlation was
found between the ATPase and RTPase activities for the
various mutants studied the two reactions were proposed to
share the same site, in agreement with previous studies
(Benarroch, 2004). A less encouraging finding for drug de-
sign was the existence of residual helicase activity that was
ATPase-independent (Bartelma et al., 2002). The limited
numberofinteractionsprovidedbythesugarandbasemoi-
eties in the ATP binding site suggests that the ATP binding
site may not be a good target for the design of competitive
Natarajan 217inhibitors. In addition, there are important questions that
still need to be addressed, such as the number of base pairs
separated at each step and the amount of ATP needed for
the reaction. Future investigations should aim to precisely
define the various structural states assumed by the NS3 en-
zyme during catalysis. This information could be particu-
larly useful in the design of “allosteric inhibitors” aimed at
preventingthestructuraltransitionsthatoccurduringcatal-
ysis.
Conclusions
Although there are still no specific vaccines or che-
motherapeutic regimes for the prevention and treatment of
denguefeveranddenguehemorrhagicfever,inrecentyears
there has been substantial progress in our understanding of
the life cycle of dengue virus, the various stages of which
represent potential targets for the development of novel an-
tiviral drugs. NS3 protein is a particularly interesting mo-
lecular target for antiviral compounds because of it central
role in the viral life cycle. The structural similarities be-
tweentheactiveproteaseandhelicaseofNS3suggestthata
compound that could hamper the dynamics of this multi-
functional enzyme would be attractive. Such a compound
could for instance target the entrance of the RNA binding
tunnel (towards the 5’ end of the RNA substrate) which is
lined by two mobile helices, or prevent protein - protein in-
teractionsbetweenNS3andNS2B.Achallengingaspectin
the search for potent, selective antiviral drugs that interfere
with multifunctional NS3 is the design of appropriate as-
says for druggable sites that are relevant for viral replica-
tion in vivo. Inhibitors of NS3pro should also be of great
benefit in combating infections by other Flaviviruses, as
well as Japanese encephalitis virus and West Nile virus.
The development of such drugs requires a more informed
structure-based drug discovery program. A further consid-
erationincludesthecostofdrugsynthesiswhichshouldnot
make the price of the final product prohibitive to poor pa-
tients in developing countries.
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